CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)

Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2016;48(4):1177-1186. Published online 2016 February 22 DOI: https://doi.org/10.4143/crt.2015.401

Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando

Cancer Research and Treatment. 2016;48(4):1177-1186

Link1

Link2 Link3

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

Edward B. Garon, Dachuang Cao, Ekaterine Alexandris, William J. John, Sergey Yurasov, Maurice Perol

Clinical Lung Cancer. 2012;13(6):505-509

Link1 Link2

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Pérol

The Lancet. 2014;384(9944):665-673

Link1 Link2

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Kiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara, Kazuhiko Yamada, Toshiaki Takahashi, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, Toshiko Koue, Takashi Nakamura, Sotaro Enatsu, Pablo Lee, David Ferry, Tomohide Tamura, Kazuhiko Nakagawa

Lung Cancer. 2016;99:186-193

Link1 Link2

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Edward B. Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos Kalofonos, Joo-Hang Kim, Steven Gans, Oddrje Te Brustugun, Sergey V. Orlov, Gebra Cuyun Carter, Annamaria H. Zimmermann, Ana B. Oton, Ekaterine Alexandris, Pablo Lee, Katharina Wolff, Victoria Jennifer Stefaniak, Mark A. Socinski, Maurice Pérol

ESMO Open. 2020;5(1):e000567

Link1 Link2 Link3

Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)

M. Reck, L. Paz-Ares, D. Moro-Sibilot, F.A. Shepherd, F. Cappuzzo, K.B. Winfree, E. Alexandris, A. Sashegyi, R. Varea, M. Pérol

Annals of Oncology. 2017;28:ii43

Link1 Link2 Link3

Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)

M. Reck, L. Paz-Ares, M. Pérol, M. Johnson, N. Pennell, S. Novello, F. Cappuzzo, P. Bidoli, A. Zimmermann, P. Lee, A. Sashegyi, R. Varea Menendez

Annals of Oncology. 2017;28:vi54-vi55

Link1 Link2 Link3

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

E.B. Garon, G.V. Scagliotti, O. Gautschi, M. Reck, M. Thomas, L.I. Docampo, H. Kalofonos, J.H. Kim, S. Gans, O.T. Brustugun, S.V. Orlov, D. Ferry, A. Melemed, G.C. Carter, A.H. Zimmermann, J.A. Treat, E. Alexandris, P. Lee, M.A. Socinski, M. Perol

European Journal of Cancer. 2015;51:S621

Link1 Link2

Ramucirumab in East Asian patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy: A pooled analysis of two randomized double-blind studies

J-Y Shih, K. Yoh, Y. Hosomi, G-C Chang, T-C Hsia, T. Tamura, R. Varea, T. Nakamura, J. Gallo, R. Cheng, S. Enatsu, K. Nakagawa

Annals of Oncology. 2017;28:x122

Link1 Link2 Link3

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

P. Bidoli, F. Cappuzzo, A. Favaretto, O. Alabiso, M. Tiseo, A. Chella, V. Gebbia, L. Pizzuti, L. Paz-Ares, M. Perol, E. Garon, P. Lee, A. Zimmermann, G. Cuyun Carter, M.R. Migliorino

Annals of Oncology. 2015;26:vi74

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.